Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | NAMPT | P43490 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 5/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434317 | 0.87 | CASR (0.81) | CASRMAPTNAMPTMEN1KMT2A | |
| SCHEMBL2430084 | 0.83 | CASR (1.00) | CASRMEN1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2430546 | 0.83 | CASR (0.76) | CASRMAPTMEN1KMT2AHTT | |
| SCHEMBL1019967 | 0.81 | SMN1; SMN2 (0.78) | CASRMAPTNAMPTMEN1KMT2A | |
| SCHEMBL2434172 | 0.80 | CASR (1.00) | CASRMAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20380337 | 0.80 | NAMPT (1.00) | CASRMAPTNAMPTMEN1KMT2A | |
| SCHEMBL20379660 | 0.79 | CASR (0.65) | CASRMAPTNAMPTMEN1KMT2A | |
| SCHEMBL4945166 | 0.79 | CASR (0.65) | CASRMAPTNAMPTMEN1KMT2A | |
| SCHEMBL2433648 | 0.79 | CASR (1.00) | CASR | |
| SCHEMBL7655911 | 0.78 | SMN1; SMN2 (0.66) | CASRMAPTNAMPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2366698-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | Galapagos SAS (FR) | 2011-09-21 | — | — | EP | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | GALAPAGOS SAS (FR) | 2008-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125424-A1 | Derivatives of urea and related diamines, methods for their manufacture, and uses therefor | UTS2R, CASR, GPR17 | CASR 2/4885MAPT 1435/4885NAMPT 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.